Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins.

This study focuses on mass spectrometry for identification, monitoring, and minimal residual disease detection of m-proteins.. The research employs high-performance liquid chromatography (HPLC) techniques to address analytical challenges in the biopharmaceutical field. Monoclonal gammopathies (MGs) are plasma cell disorders defined by the clonal expansion of plasma cells, resulting in the characteristic excretion of a monoclonal immunoglobulin (M-protein). M-protein detection and quantification are integral parts of the diagnosis and monitoring of MGs. Novel treatment modalities impose new challenges on the traditional electrophoretic and... Research Background and Significance Monoclonal gammopathies (MGs) represent a group of plasma cell disorders characterized by the clonal proliferation of plasma cells, which secrete a pathognomonic monoclonal immunoglobulin, commonly referred to as M-protein. Accurate detection and quantification of M-proteins are pivotal for diagnosis, disease monitoring, and evaluating minimal residual disease (MRD) in affected patients. Traditional methods, including electrophoretic techniques, have been employed extensively but face limitations in sensitivity and specificity, especially when evaluating low disease burden or treatment response. The advent of mass spectrometry (MS), coupled with high-performance liquid chromatography (HPLC), offers enhanced analytical capabilities, overcoming challenges posed by novel therapeutic modalities that alter M-protein characteristics. This study underscores the integration of HPLC and MS to develop robust, sensitive, and reliable methods for M-protein identification and quantification, thereby advancing clinical biopharmaceutical applications. Experimental Design and Methodology The study employed a val